now loading...
Wealth Asia Connect Middle East Treasury & Capital Markets Europe ESG Forum TechTalk
Treasury & Capital Markets / On The Move
The Carlyle Group appoints new senior advisor to Asia buyout team
Hong Kong – Global alternative asset manager, The Carlyle Group has announced the appointment of Jesse Wu, former Chairman of Johnson & Johnson China and former Worldwide Chairman of the Johnson & Johnson Consumer Group, as a Senior Advisor to the group’s Asia buyout team. Mr. Wu brings to Carlyle nearly 30 years of experience in the healthcare and related sectors.
The Asset 21 Jun 2016
Hong Kong – Global alternative asset manager, The Carlyle Group has announced the appointment of Jesse Wu, former chairman of Johnson & Johnson China and former Worldwide chairman of the Johnson & Johnson Consumer Group, as a senior advisor to the group’s Asia buyout team. Wu brings to Carlyle nearly 30 years of experience in the healthcare and related sectors.
X.D. Yang, managing director and co-head of the Carlyle Asia buyout team, said, “We are thrilled to welcome Jesse Wu, a global business leader and experienced healthcare expert, as an advisor to Carlyle. With his deep healthcare industry expertise and highly respected senior management capabilities, Jesse will be a great resource for our team and our portfolio companies as we continue to expand our investments in the fast-growing healthcare sector and other related industries in China and across Asia. Our buyout team in Asia has been a leader in investing in healthcare with more than $1.3 billion of equity invested in seven companies across the Asia-Pacific region and we remain greatly excited about future investment opportunities.”
Wu said, “I am delighted to work with The Carlyle Group. Having been in the healthcare industry for almost three decades, I see fundamental changes happening in this space, ranging from changing demographic trends to more favorable regulatory reforms, as well as exciting, new technologies and treatments. I look forward to engaging with the team and leveraging my industry experience to advise on attractive investment opportunities and help create value for Carlyle’s portfolio of companies.”
Wu joined Johnson & Johnson in 1989 and served as Chairman of Johnson & Johnson China and as a member of the company’s management committee from 2013 to 2016. During his 26-year tenure at Johnson & Johnson, Wu served across multiple roles, including as Worldwide Chairman of the Johnson & Johnson Consumer Group and Company Group Chairman for Global Markets.
The Carlyle Asia buyout team has extensive experience in the rapidly growing healthcare sector in the Asia-Pacific region, excluding Japan. To date, the team has invested more than $1.3 billion of equity in seven companies. Its recent and historical investments include Meinian Onehealth, Zhongmei Healthcare, MicroPort Scientific Corporation, and Haier Bio-Medical and Laboratory Products in China; Global Health and Metropolis Healthcare in India; and Healthscope in Australia. Globally, Carlyle has invested more than $8.4 billion of equity in over 50 investments in the healthcare sector.  
Conversation
Amy Kam
Amy Kam
senior portfolio manager, emerging markets corporate debt
Aviva Investors
- JOINED THE EVENT -
In-person roundtable
Securing the future
View Highlights
Conversation
Diwakar Vijayvergia
Diwakar Vijayvergia
senior vice president and portfolio manager, Asia fixed income
AllianceBernstein
- JOINED THE EVENT -
18th Asia Bond Markets Summit - Asean Edition
Investing in the new normal
View Highlights